Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

New Study from Neuvivo’s NP001: First to Link Regulation of the Innate Immune System with Respiratory Function in ALS

March 31, 2023 0

New Study from Neuvivo On March 30, 2023, Neuvivo – a private Company, announced the publication of …

The EU CHMP Agency Recommended Approval of TG Therapeutics Firm’s BRIUMVI™ for Relapsing Forms of MS in Adults

March 31, 2023 0

TG Therapeutics TG Therapeutics, Inc. (TGTX) announced today that the Committee for Medicinal Products for Human …

The U.S. FDA Accepted Checkpoint Therapeutics Biotech BLA for Cosibelimab

March 31, 2023 0

Checkpoint Therapeutics Checkpoint Therapeutics (CKPT) is a clinical-stage immunotherapy and targeted oncology company focused on the …

BrainStorm Cell Therapeutics: Another Clinical-Stage Small Firm’s Product for the Devastating Disease ALS

March 27, 2023 0

BrainStorm Cell Therapeutics Inc BrainStorm Cell Therapeutics Inc (BCLI) develops innovative autologous adult stem cell therapeutics …

An Important New Licensing Agreement Between Vertex Pharmaceuticals and CRISPR Therapeutics

March 27, 2023 0

Vertex Pharmaceuticals and Crispr Therapeutics Agreement Aims at Accelerating Vertex's Hypo immune Cell Therapies for Type …

Vertex Pharmaceuticals Recent Impacting News

March 24, 2023 0

Important News from Vertex Vertex Pharmaceuticals (VRTX) is a worldwide biotechnology company that invests in scientific …

23andMe Teams Up with Novartis on Lipoprotein(a) Education for its Customers

March 24, 2023 0

23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease March …

CymaBay Therapeutics’ Clinical Trials Brought Proof of Concept of its Technology and More

March 21, 2023 0

CymaBay Therapeutics CymaBay Therapeutics (CBAY) is a clinical-stage biopharmaceutical firm focused on improving the lives of people …

As Expected, Seagen Was Taken Over, the Buyer is Pfizer.

March 13, 2023 0

Pfizer to Acquire Seagen Pfizer (PFE) is to acquire Seagen (SGEN) for $229 per share in …

What We Are Looking for in a Bear Market

March 11, 2023 0

The Stock Market The volatility continues in the Bear market with investors not knowing what to …

Why the Current Interest in Ventyx Biosciences

March 7, 2023 0

The Current Interest in Ventyx Biosciences Answered 1. Ventyx Biosciences Focus We like the fact that Ventyx …

Intellia Therapeutics Announces FDA Clearance of IND Application for NTLA-2002 Therapy for the Treatment of Hereditary Angioedema

March 2, 2023 0

Intellia Therapeutics Intellia Therapeutics (NTLA) announced that the U.S. FDA has cleared the company’s Investigational New …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

New Study from Neuvivo’s NP001: First to Link Regulation of the Innate Immune System with Respiratory Function in ALS

The EU CHMP Agency Recommended Approval of TG Therapeutics Firm’s BRIUMVI™ for Relapsing Forms of MS in Adults

The U.S. FDA Accepted Checkpoint Therapeutics Biotech BLA for Cosibelimab

BrainStorm Cell Therapeutics: Another Clinical-Stage Small Firm’s Product for the Devastating Disease ALS

An Important New Licensing Agreement Between Vertex Pharmaceuticals and CRISPR Therapeutics

Vertex Pharmaceuticals Recent Impacting News

23andMe Teams Up with Novartis on Lipoprotein(a) Education for its Customers

CymaBay Therapeutics’ Clinical Trials Brought Proof of Concept of its Technology and More

As Expected, Seagen Was Taken Over, the Buyer is Pfizer.

What We Are Looking for in a Bear Market

Why the Current Interest in Ventyx Biosciences

Intellia Therapeutics Announces FDA Clearance of IND Application for NTLA-2002 Therapy for the Treatment of Hereditary Angioedema

Apellis Pharmaceuticals: A Biopharmaceutical Firm That We Like

Why Travere Therapeutics’ Stocks Did Not Fall During This Tuesday’s Bad Market

Evaluating Regenxbio Clinical Performance of RGX-314 Using the Navxpress™ Manufacturing Platform Process

Endogena Therapeutics: Treating Retinitis Pigmentosa and Other Devastating Degenerative Diseases

Xenon Pharmaceuticals: A Newly Selected Clinical-Stage Firm. See Also: Recently Selected Clinical Stage Firms

Merck: KEYTRUDA Plus Chemo as First-Line Treatment for Stage III-IV or Recurrent Endometrial Carcinoma

CytomX: Why Does Good News from This Firm Cause Its Stock to Move South Instead of North?

Could We Soon Have a Specific Treatment for the Rare Disease IgA Nephritis?